Scotia Pares Business To Four Therapeutic Sectors
Scotia has started restructuring its business to focus on four coreareas, - oncology, diabetes, psychiatry and dermatology - and will offer up its other interests for licensing, said chief executive David Horrobin at the firm's 1996 annual results meeting on March 25.
The other R&D sectors, notably arthritis, female health care and cardiovascular disease, will continue until all ongoing trials are completed, but there will be no further investment in these areas. The projects will either be licensed out, sold or dropped, said Dr Horrobin (for listing see table page 21).
Hand-in-hand with this refocusing of R&D will be a restructuring of the business so that each division will operate as a separate company, he added, noting that this has already worked extremely well with Efamol, the nutritionals business. At the moment, the divisions comprise Scotia Pharmaceuticals, Scotia Quanta-Nova (focusing on photodynamic therapy), Efamol and LipidTeknik of Sweden, focusing on drug delivery.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze